Skip to main content

Conmed Value Stock - Dividend - Research Selection

Conmed

ISIN: US2074101013 , WKN: 886793

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician\'s office electrosurgical product used by dermatologists. The company\'s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


CONMED (CNMD) Price Target Decreased by 10.37% to 49.37

2025-12-21

Conmed Taking On More Pain In The Pursuit Of Future Gain

2025-12-14
Conmed (CNMD) nears decade lows but boosts margins by refocusing on higher-growth products.

B of A Securities Maintains CONMED (CNMD) Neutral Recommendation

2025-12-08

CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio

2025-12-08
CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.

Is CONMED (CNMD) Trading Niche Biliary Devices For A Higher-Margin Endoscopy Future?

2025-12-07
In early December 2025, Olympus, W. L. Gore & Associates and CONMED announced that US distribution of the GORE VIABIL Biliary Endoprosthesis will shift from CONMED to Olympus on 1 January 2026, with CONMED supporting orders and service through 31 December 2025 for this fully covered self-expanding metal stent used in biliary strictures. This transition highlights how CONMED’s endoscopy portfolio is evolving as it cedes distribution of a niche biliary device while investors focus on its...

Looking at the Narrative for CONMED After Analyst Model Tweaks and Capital Moves

2025-12-07
CONMED's latest price target update keeps fair value steady at $54.00 per share, even as analysts fine tune their assumptions around growth and risk. The slightly lower discount rate and modestly reduced revenue growth outlook reflect a more balanced view of execution risk that still supports the stock's mid term narrative. Stay tuned to learn how you can track these evolving assumptions and stay ahead of future narrative shifts around CONMED's valuation. Stay updated as the Fair Value for...

Sector Update: Health Care Stocks Lower Late Afternoon

2025-12-05
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 0.3% and

Why Is Conmed (CNMD) Up 0.1% Since Last Earnings Report?

2025-12-05
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why CONMED (CNMD) Shares Are Plunging Today

2025-12-05
Shares of medical tech company CONMED (NYSE:CNMD) fell 6.2% in the morning session after the company announced its plan to exit its gastroenterology product lines as part of a broader portfolio adjustment.

CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines

2025-12-05
LARGO, Fla., December 05, 2025--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair.